SG301

SG301 is an investigational agent whose form is not stated in the registry developed by Hangzhou Sumgen Biotech. Its target is CD38 (the sponsor names CD38). The sponsor states: Humanized anti-CD38 monoclonal antibody; a subcutaneous formulation (SG301 SC) has also been approved for clinical trials. ClinicalTrials.gov describes the intervention as: Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06508983 (A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients), in multiple myeloma. The largest, NCT06508983, plans to enrol 360 participants with primary completion expected 2027-03-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.